Search
Learn more on the EHA Campus
EHA has developed EHA Campus courses related to previous EHA-LSHBT Virtual Hematology Updates. The aim of the courses is to add to your learning experience, making the information discussed during the webinars available in an interactive and engaging way.
Read moreRegistration & accommodation
Registration is closed
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting
Digital meeting materials including the program and abstract book
Networking opportunities during breaks, receptions and dinners
Catering during meeting hours incl.
Burnout - it doesn't just happen to someone else
Burnout - it doesn't just happen to someone else
By Dr. med.
Registration & accommodation
Register here
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.
Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast
“Congratulations – your abstract was accepted for the upcoming EHA congress”.
Read moreMore than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read moreMeet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Meet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read moreBreakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?
APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…
Read more